Contract research firm IQVIA Holdings beat Wall Street estimates for fourth-quarter profit and revenue on Thursday, helped by the demand for its healthcare data and analytics services.

Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.

Lupin and Natco receive US FDA approval for generic Tracleer tablets for oral suspension: Our Bureau, Mumbai Monday, February 10, 2025, 15:45 Hrs [IST] Global pharma major Lupin L ...

IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...

Bosentan Tablets for Oral Suspension are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital ...

These issues were primarily attributed to reorganizations within large pharmaceutical companies and reduced spending in the biopharma sector. Analysts have noted that while IQVIA is less dependent ...

Celltrions Vegzelma becomes Europes top prescribed anticancer drug in two years Celltrions cancer treatment Vegzelma achieves impressive market dominance in Europe within two years ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

Scott EvangelistaMr. Evangelista brings over 30 years of pharmaceutical leadership experience to the board. He is currently ...

The evolution of protocol management within eQMS represents another significant advance in clinical trials. Version control ...